Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine-antibody combo takes on pancreatic cancer

NCT ID NCT05846516

Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 5 times

Summary

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination can improve survival compared to standard care. About 58 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

59 people

The number who actually took part.

Started

May 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria * Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) * ECOG performance status of 0 or 1. * Patients with advanced or metastatic disease who completed at least 16 weeks of standard of care systemic chem-/chemoradiotherapy and achieved a partial response or stable disease. * Patients who underwent confirmed R0 or R1 resection and completed at least 3 months of combined peri-adjuvant multiagent chemotherapy. * No evidence of disease progression or recurrence. * Start of study treatment within 12 weeks from the last curative treatment (resected PDAC). * Patient must have completed 8-12 cycles of FOLFIRINOX or mFOLFIRINOX either as adjuvant, neoadjuvant, or perioperative (Part C) * Life expectancy at least 12 months (resected PDAC), or at least 6 months (advanced/metastatic PDAC). * Archival tumor tissue availability for central KRAS analysis and research. Key exclusion criteria * Not yet recovered from surgery (resected PDAC). * Gastro-intestinal bowel obstruction. * Other malignancy within the last 3 years. * Prior chemotherapy or targeted small molecule therapy within 14 (locally advanced/metastatic PDAC) or 28 (resected PDAC) days from initiation of study treatment. * Prior radiotherapy within 14 days (advanced/metastatic PDAC). No prior radiotherapy. in resected PDAC * Prior use of immunotherapeutic agents, including but not limited to checkpoint inhibitors or VSV-based agents. * Diagnosis of immunodeficiency, and/or history of allogeneic organ transplant * Chronic systemic treatment with steroids or other immunosuppressive medications. * Active autoimmune disease requiring systemic treatment within the last 2 years. * Chronic or concurrent active infectious disease requiring systemic antibodies, antifungal, or antiviral treatment * Major (according to the Investigator's judgment) surgery within 12 weeks from initiation of study treatment * Use of Tamoxifen within 1 month prior to start of study treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Asklepios Kliniken Hamburg GmbH

    Hamburg, 22763, Germany

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, 1011, Switzerland

  • Clara Campal Comprehesive Cancer Center

    Madrid, 28050, Spain

  • Hopitaux Universitaires de Geneve (HUG)

    Geneva, CH-1205, Switzerland

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28007, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, 14004, Spain

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Orlando Health Cancer Institute

    Orlando, Florida, 32806, United States

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island

    New York, New York, 10016, United States

  • START South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University Hospital Bern

    Bern, 3010, Switzerland

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of California Los Angeles

    Santa Monica, California, 90404, United States

  • University of Colorado Cancer Center

    Aurora, Colorado, 80045, United States

  • University of Florida

    Gainesville, Florida, 32610, United States

  • University of Southern California

    Los Angeles, California, 90033, United States

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia, 22031, United States

  • Virginia Mason Medical Center

    Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.